SL
Siren LLC Portfolio holdings
AUM
$1.93B
This Quarter Return
-13.7%
1 Year Return
+118.08%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.77B
AUM Growth
+$1.77B
(-22%)
Cap. Flow
-$54.5M
Cap. Flow
% of AUM
-3.08%
Top 10 Holdings %
Top 10 Hldgs %
50.37%
Holding
140
New
23
Increased
28
Reduced
41
Closed
24
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$64.3M |
| 2 |
Disc Medicine
IRON
|
$53.2M |
| 3 |
Soleno Therapeutics
SLNO
|
$26.8M |
| 4 |
Edgewise Therapeutics
EWTX
|
$21.2M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$14.7M |
Top Sells
| 1 |
argenx
ARGX
|
$70.8M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$49.8M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$42.2M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$38.9M |
| 5 |
Cytokinetics
CYTK
|
$18.9M |
Sector Composition
| 1 | Healthcare | 89.75% |
| 2 | Technology | 5.2% |
| 3 | Communication Services | 2.41% |
| 4 | Consumer Discretionary | 1.21% |
| 5 | Real Estate | 0.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Pinduoduo
PDD
$177B
| $6.26M | 0.35% |
52,901
| – | – |
|
52
Spyre Therapeutics
SYRE
$1.02B
| $5.95M | 0.34% |
368,598
-5,402
| -1% | -$87.2K |
|
53
Gossamer Bio
GOSS
$587M
| $5.73M | 0.32% |
5,208,968
| – | – |
|
54
Oric Pharmaceuticals
ORIC
$1.03B
| $5.62M | 0.32% |
1,007,575
| – | – |
|
|
UPB
55
Upstream Bio, Inc. Common Stock
UPB
$1.08B
| $4.83M | 0.27% |
788,450
-11,550
| -1% | -$70.7K |
|
56
NVIDIA
NVDA
$4.15T
| $4.82M | 0.27% |
44,432
-4,500
| -9% | -$488K |
|
57
TSMC
TSM
$1.2T
| $4.73M | 0.27% |
28,500
+13,500
| +90% | +$2.24M |
|
58
Datadog
DDOG
$46.2B
| $4.71M | 0.27% |
47,425
+17,000
| +56% | +$1.69M |
|
59
Neumora Therapeutics
NMRA
$283M
| $4.36M | 0.25% |
4,358,283
-37,817
| -0.9% | -$37.8K |
|
60
JFrog
FROG
$5.58B
| $4.21M | 0.24% |
131,616
+11,500
| +10% | +$368K |
|
61
Dynatrace
DT
$15.1B
| $4.14M | 0.23% |
87,729
+5,000
| +6% | +$236K |
|
|
MTSR
62
Metsera, Inc. Common Stock
MTSR
$3.75B
| $4.08M | 0.23% |
+150,000
| New | +$4.08M |
|
63
Rocket Pharmaceuticals
RCKT
$358M
| $3.94M | 0.22% |
591,263
-8,737
| -1% | -$58.3K |
|
64
Salesforce
CRM
$245B
| $3.92M | 0.22% |
+14,600
| New | +$3.92M |
|
65
New Oriental
EDU
$7.98B
| $3.8M | 0.21% |
79,500
+11,000
| +16% | +$526K |
|
|
RAPP
66
Rapport Therapeutics
RAPP
$549M
| $3.8M | 0.21% |
378,469
-5,728
| -1% | -$57.5K |
|
67
IonQ
IONQ
$12.2B
| $3.75M | 0.21% |
170,000
| – | – |
|
|
IGMS
68
DELISTED
IGM Biosciences
IGMS
| $3.74M | 0.21% |
3,255,826
-74,596
| -2% | -$85.8K |
|
|
WHWK
69
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| $3.71M | 0.21% |
+2,082,000
| New | +$3.71M |
|
70
Instil Bio
TIL
$196M
| $3.54M | 0.2% |
203,933
+11,500
| +6% | +$200K |
|
71
Tango Therapeutics
TNGX
$745M
| $3.51M | 0.2% |
2,565,342
-38,555
| -1% | -$52.8K |
|
|
VIGL
72
DELISTED
Vigil Neuroscience
VIGL
| $3.5M | 0.2% |
1,967,064
-23,974
| -1% | -$42.7K |
|
|
SION
73
Sionna Therapeutics, Inc. Common Stock
SION
$1.08B
| $3.4M | 0.19% |
+325,000
| New | +$3.4M |
|
|
NBIS
74
Nebius Group N.V. Class A Ordinary Shares
NBIS
$15.7B
| $2.96M | 0.17% |
140,000
+20,000
| +17% | +$422K |
|
75
Foghorn Therapeutics
FHTX
$298M
| $2.63M | 0.15% |
720,720
| – | – |
|